,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,IL36A,"FIL1, FIL1E, IL-1F6, IL1(EPSILON), IL1F6, MGC129552, MGC129553",ENSG00000136694,"Interleukin 36, alpha",2,113005461-113008044,Predicted intracellular proteins,Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,1237,esophagus: 459.4;tonsil: 105.4,endometrium: 0.2,Cell line enhanced,,MOLT-4: 1.0
1,TMPRSS11B,,ENSG00000185873,"Transmembrane protease, serine 11B",4,68226653-68245720,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,Head and neck cancer:6.91e-4 (favourable),Group enriched,Group enriched,184,esophagus: 311.6;tonsil: 74.5,"cervix, uterine: 1.0",Not detected,,
2,TMPRSS11A,ECRG1,ENSG00000187054,"Transmembrane protease, serine 11A",4,67909385-67964140,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Group enriched,Group enriched,64,esophagus: 96.0;tonsil: 26.0,"cervix, uterine: 0.9",Not detected,,
3,TMPRSS11D,,ENSG00000153802,"Transmembrane protease, serine 11D",4,67820876-67884032,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA052834,Uncertain,,,,,Group enriched,Group enriched,39,esophagus: 70.5;tonsil: 30.6,"cervix, uterine: 1.3",Not detected,,
4,LCE3E,LEP17,ENSG00000185966,Late cornified envelope 3E,1,152565654-152566772,Predicted intracellular proteins,Evidence at protein level,,,,,,,Group enriched,Group enriched,35,esophagus: 9.6;skin: 9.0;tonsil: 18.1,breast: 0.3,Not detected,,
5,SLURP1,"ANUP, ARS, ArsB, LY6LS, MDM",ENSG00000126233,Secreted LY6/PLAUR domain containing 1,8,142740944-142742411,"Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA050967,Approved,,,,,Tissue enhanced,Group enriched,33,esophagus: 740.6;skin: 297.1,tonsil: 15.7,Cell line enhanced,,HaCaT: 1.1;MCF7: 1.1;T-47d: 2.4
6,CNFN,PLAC8L2,ENSG00000105427,Cornifelin,19,42387019-42390287,Predicted intracellular proteins,Evidence at protein level,"HPA049073, HPA053997",Enhanced,,Approved,Microtubules<br>Cytokinetic bridge,Thyroid cancer:4.02e-5 (favourable),Expressed in all,Group enriched,32,esophagus: 1158.0;skin: 272.5;tonsil: 260.7,breast: 17.6,Cell line enhanced,,A549: 17.1;HEK93: 24.4
7,SPINK5,"DKFZp686K19184, FLJ21544, FLJ97536, FLJ97596, FLJ99794, LEKTI, LETKI, NETS, NS, VAKTI",ENSG00000133710,"Serine peptidase inhibitor, Kazal type 5",5,148025683-148137289,"Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA009067, HPA011351, CAB015347",Enhanced,,Enhanced,Vesicles,,Tissue enhanced,Group enriched,26,esophagus: 1130.0;skin: 383.9;tonsil: 270.0,breast: 22.9,Cell line enhanced,,HaCaT: 13.2;HeLa: 14.7;Karpas-707: 13.8
8,SPINK7,"ECG2, ECRG2",ENSG00000145879,"Serine peptidase inhibitor, Kazal type 7 (putative)",5,148312419-148315922,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA036294,Enhanced,,,,,Group enriched,Group enriched,25,esophagus: 416.8;tonsil: 106.3,"cervix, uterine: 10.5",Not detected,,
9,BPIFB2,"BPIL1, C20orf184, dJ726C3.2, LPLUNC2",ENSG00000078898,BPI fold containing family B member 2,20,33007600-33023709,"Plasma proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA049491, HPA060121",Enhanced,,Approved,Vesicles,Endometrial cancer:1.97e-5 (favourable),Group enriched,Group enriched,23,esophagus: 98.5;salivary gland: 90.5,"cervix, uterine: 4.0",Cell line enriched,418.0,Hep G2: 146.8
10,NCCRP1,"FBXO50, LOC342897, NCCRP-1",ENSG00000188505,Non-specific cytotoxic cell receptor protein 1 homolog (zebrafish),19,39196961-39201884,Predicted intracellular proteins,Evidence at protein level,HPA052812,Uncertain,,Approved,Mitochondria,Endometrial cancer:1.01e-4 (unfavourable),Mixed,Group enriched,22,esophagus: 263.4;skin: 175.5;tonsil: 113.3,breast: 8.2,Cell line enriched,7.0,SK-BR-3: 23.1
11,SPRR2B,,ENSG00000196805,Small proline rich protein 2B,1,153070224-153070840,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Tissue enriched,Group enriched,18,esophagus: 30.3;skin: 17.1;testis: 8.2;tonsil: 14.1,ovary: 0.9,Not detected,,
12,SPRR2E,,ENSG00000203785,Small proline rich protein 2E,1,153093135-153106184,Predicted intracellular proteins,Evidence at transcript level,,,,,,Urothelial cancer:9.47e-4 (unfavourable),Tissue enhanced,Group enriched,18,esophagus: 2005.4;skin: 804.8;tonsil: 459.7,breast: 61.4,Cell line enriched,9.0,hTCEpi: 12.1
13,FAM83C,"C20orf128, dJ614O4.7",ENSG00000125998,Family with sequence similarity 83 member C,20,35285731-35292401,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB034227, HPA049978",Uncertain,,,,,Tissue enhanced,Group enriched,17,esophagus: 19.8;skin: 43.0,tonsil: 1.8,Not detected,,
14,KRT33A,"Ha-3I, Krt1-3, KRTHA3A",ENSG00000006059,Keratin 33A,17,41346092-41350812,Predicted intracellular proteins,Evidence at protein level,HPA055194,Supported,,,,,Tissue enhanced,Group enriched,15,esophagus: 1.4;testis: 1.6,all non-specific tissues: 0.0,Cell line enhanced,,RT4: 1.1
15,PI3,"cementoin, ELAFIN, ESI, SKALP, WAP3, WFDC14",ENSG00000124102,Peptidase inhibitor 3,20,45174876-45176544,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB009449, HPA017737",Enhanced,,Approved,Plasma membrane,"Renal cancer:1.94e-8 (unfavourable), Ovarian cancer:3.84e-6 (unfavourable), Pancreatic cancer:6.89e-4 (unfavourable), Breast cancer:6.94e-4 (favourable)",Tissue enhanced,Group enriched,15,esophagus: 2285.4;tonsil: 1739.8,appendix: 133.6,Group enriched,7.0,EFO-21: 78.9;HaCaT: 92.0;PC-3: 163.0
16,FAM25C,bA164N7.4,ENSG00000276430,Family with sequence similarity 25 member C,10,47995355-47999791,Predicted intracellular proteins,Evidence at transcript level,HPA044808,Uncertain,,,,,Tissue enhanced,Group enriched,14,breast: 5.3;esophagus: 4.0;skin: 9.0;small intestine: 4.3;tonsil: 2.1,"skeletal muscle,testis: 0.3",Cell line enriched,5.0,SK-BR-3: 12.1
17,KRT32,"Ha-2, KRTHA2",ENSG00000108759,Keratin 32,17,41459811-41467429,Predicted intracellular proteins,Evidence at protein level,,,,,,,Not detected,Group enriched,14,esophagus: 7.4;skin: 2.4,breast: 0.3,Not detected,,
18,FABP12,,ENSG00000197416,Fatty acid binding protein 12,8,81524981-81531378,Predicted intracellular proteins,Evidence at protein level,HPA044041,Approved,,,,,Tissue enhanced,Group enriched,13,esophagus: 4.3;testis: 15.4,lung: 0.7,Not detected,,
19,DSC3,"CDHF3, DSC, DSC1, DSC2, DSC4",ENSG00000134762,Desmocollin 3,18,30990008-31042815,"Disease related genes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB037328, HPA049265, HPA073937",Enhanced,,Enhanced,Plasma membrane<br>Cell Junctions,Urothelial cancer:1.04e-5 (unfavourable),Tissue enhanced,Group enriched,12,esophagus: 119.1;skin: 454.8,tonsil: 24.8,Cell line enhanced,,HaCaT: 242.4;hTCEpi: 115.0;hTERT-HME1: 89.5
20,SBSN,"HLAR698, UNQ698",ENSG00000189001,Suprabasin,19,35523367-35528351,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA062568, HPA067734",Enhanced,,Approved,Vesicles,,Group enriched,Group enriched,12,esophagus: 1055.9;skin: 2690.8,tonsil: 151.8,Cell line enhanced,,ASC diff: 42.6;ASC TERT1: 75.3;HSkMC: 106.4;U-2197: 48.0;U-87 MG: 117.4
21,AC011513.3,,ENSG00000267881,,19,41708612-41761282,Predicted secreted proteins,Evidence at transcript level,HPA011041,Approved,,,,,Tissue enhanced,Group enriched,11,colon: 41.2;esophagus: 10.3,appendix: 2.4,Not detected,,
22,C10orf99,"AP-57, CSBF, FLJ21763, RLLV1833, UNQ1833",ENSG00000188373,Chromosome 10 open reading frame 99,10,84173738-84185294,Predicted secreted proteins,Evidence at protein level,HPA050920,Enhanced,,,,Renal cancer:1.20e-5 (unfavourable),Mixed,Group enriched,11,colon: 239.2;esophagus: 185.4;rectum: 264.2,urinary bladder: 20.8,Cell line enriched,6.0,RT4: 37.2
23,CRCT1,"C1orf42, NICE-1",ENSG00000169509,Cysteine rich C-terminal 1,1,152514502-152516010,Predicted intracellular proteins,Evidence at protein level,,,,,,Pancreatic cancer:7.03e-4 (unfavourable),Tissue enhanced,Group enriched,11,esophagus: 84.0;skin: 82.8;tonsil: 17.6,breast: 5.6,Cell line enriched,14.0,CAPAN-2: 4.5
24,CYP2C18,"CPCI, CYP2C, CYP2C17, P450IIC17",ENSG00000108242,Cytochrome P450 family 2 subfamily C member 18,10,94683621-94736190,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,11,duodenum: 103.1;esophagus: 24.6;gallbladder: 24.5;liver: 97.8;small intestine: 88.1;stomach: 62.2,tonsil: 6.2,Cell line enhanced,,BEWO: 3.0
25,GRHL3,"SOM, TFCP2L4",ENSG00000158055,Grainyhead like transcription factor 3,1,24319322-24364482,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors",Evidence at protein level,HPA059960,Enhanced,,Approved,Nucleoplasm,,Tissue enhanced,Group enriched,11,esophagus: 85.1;skin: 50.1;tonsil: 22.6;urinary bladder: 28.1,testis: 4.3,Cell line enhanced,,BEWO: 43.8;HaCaT: 32.1;MCF7: 43.8;RT4: 51.5
26,HEPHL1,DKFZp686F22190,ENSG00000181333,Hephaestin like 1,11,94021361-94113751,Predicted membrane proteins,Evidence at protein level,HPA031517,Uncertain,,,,Cervical cancer:4.94e-4 (unfavourable),Tissue enriched,Group enriched,11,esophagus: 3.2;tonsil: 9.4,testis: 0.5,Cell line enhanced,,HaCaT: 1.4;HBEC3-KT: 2.0
27,LY6D,E48,ENSG00000167656,Lymphocyte antigen 6 family member D,8,142784880-142786592,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA024755, HPA064317",Enhanced,,,,"Pancreatic cancer:1.94e-6 (unfavourable), Renal cancer:1.20e-4 (unfavourable)",Group enriched,Group enriched,11,esophagus: 631.6;skin: 717.0,tonsil: 61.0,Cell line enriched,26.0,A-431: 128.0
28,LYNX1,,ENSG00000283992,Ly6/neurotoxin 1,8,142764338-142769844,"Predicted secreted proteins, Transporters",Evidence at protein level,,,,,,,,Group enriched,11,esophagus: 315.6;skin: 108.1,tonsil: 19.9,Group enriched,16.0,EFO-21: 5.6;HaCaT: 24.1
29,PKP1,B6P,ENSG00000081277,Plakophilin 1,1,201283452-201332993,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA027221, HPA027589, CAB033130",Enhanced,,Enhanced,Nucleoplasm,,Tissue enhanced,Group enriched,11,esophagus: 281.6;skin: 821.6,prostate: 51.7,Cell line enhanced,,HaCaT: 205.1;HBEC3-KT: 102.1;hTCEpi: 358.4;hTERT-HME1: 100.7;PC-3: 176.6
30,PLEKHN1,DKFZP434H2010,ENSG00000187583,Pleckstrin homology domain containing N1,1,966497-975865,Predicted intracellular proteins,Evidence at protein level,HPA031742,Uncertain,,Approved,Nuclear speckles,Renal cancer:4.97e-5 (unfavourable),Mixed,Group enriched,11,esophagus: 16.9;skin: 44.0,urinary bladder: 2.7,Cell line enhanced,,HaCaT: 22.0
31,SLC39A2,ZIP2,ENSG00000165794,Solute carrier family 39 member 2,14,20999255-21001871,Predicted membrane proteins,Evidence at protein level,HPA030489,Uncertain,,,,,Mixed,Group enriched,11,esophagus: 19.0;prostate: 19.2;seminal vesicle: 46.9;skin: 34.1,breast: 2.6,Cell line enriched,67.0,HaCaT: 20.5
32,UPK3B,"FLJ32198, MGC10902, p35, UPIIIb",ENSG00000243566,Uroplakin 3B,7,76510428-76516521,"Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA010506,Approved,,Approved,Nucleus<br>Vesicles<br>Cytosol,,Group enriched,Group enriched,11,esophagus: 12.4;lung: 29.8;urinary bladder: 11.0,tonsil: 1.6,Group enriched,8.0,A549: 12.0;CAPAN-2: 41.9;HaCaT: 8.6;RT4: 26.3;T-47d: 25.4
33,PADI3,PDI3,ENSG00000142619,Peptidyl arginine deiminase 3,1,17249098-17284233,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA043739,Uncertain,,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:1.55e-11 (unfavourable), Endometrial cancer:3.22e-4 (unfavourable)",Tissue enhanced,Group enriched,10,esophagus: 3.7;seminal vesicle: 4.9;urinary bladder: 10.2,epididymis: 0.6,Cell line enhanced,,EFO-21: 13.2;RT4: 13.9;T-47d: 12.0
34,CERS3,"LASS3, MGC27091",ENSG00000154227,Ceramide synthase 3,15,100400395-100544995,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA006092, HPA024356",Approved,,Approved,Nucleoplasm,,Tissue enhanced,Group enriched,9,esophagus: 48.1;skin: 60.5;testis: 32.3;tonsil: 14.3,breast: 4.3,Cell line enriched,6.0,hTCEpi: 47.1
35,EVPL,EVPK,ENSG00000167880,Envoplakin,17,76004502-76027452,Predicted intracellular proteins,Evidence at protein level,"CAB002220, HPA053969",Enhanced,,Supported,Intermediate filaments<br>Cytosol,,Mixed,Group enriched,9,esophagus: 77.5;skin: 111.0,duodenum: 10.7,Cell line enhanced,,HaCaT: 51.8;RT4: 68.1;T-47d: 50.1
36,IL20RB,"DIRS1, FNDC6, IL-20R2, MGC34923",ENSG00000174564,Interleukin 20 receptor subunit beta,3,136946230-137011085,Predicted membrane proteins,Evidence at protein level,HPA063914,,,Approved,Vesicles<br>Cytosol,"Renal cancer:0.00e+0 (unfavourable), Pancreatic cancer:1.44e-4 (unfavourable)",Group enriched,Group enriched,9,esophagus: 56.6;skin: 165.5,breast: 12.4,Cell line enhanced,,HaCaT: 70.0;HBEC3-KT: 93.7;HHSteC: 70.6;hTCEpi: 372.4;hTERT-HME1: 73.1
37,KRT5,"EBS2, KRT5A",ENSG00000186081,Keratin 5,12,52514575-52520687,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB000027, CAB000129, HPA059479",Enhanced,,Supported,Intermediate filaments,Breast cancer:1.27e-4 (favourable),Tissue enhanced,Group enriched,9,esophagus: 3256.1;skin: 5996.8,tonsil: 516.9,Group enriched,6.0,HaCaT: 2557.9;HBEC3-KT: 3723.5;hTCEpi: 8392.0
38,PGLYRP3,"PGLYRPIalpha, PGRP-Ialpha, PGRPIA",ENSG00000159527,Peptidoglycan recognition protein 3,1,153297862-153310718,Predicted secreted proteins,Evidence at protein level,HPA030369,Uncertain,,,,,Tissue enhanced,Group enriched,9,esophagus: 42.8;skin: 87.1,tonsil: 6.8,Group enriched,15.0,HaCaT: 3.4;HDLM-2: 1.4;hTCEpi: 1.0
39,S100A8,"60B8AG, CAGA, CFAG, CGLA, MRP8, P8",ENSG00000143546,S100 calcium binding protein A8,1,153390032-153391188,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002791, HPA024372",Enhanced,,Supported,Intermediate filaments,Renal cancer:8.94e-7 (unfavourable),Expressed in all,Group enriched,9,bone marrow: 14915.7;esophagus: 12755.4;tonsil: 4867.3,appendix: 1232.5,Group enriched,28.0,hTCEpi: 103.6;SK-BR-3: 396.8;THP-1: 195.3
40,SPRR2F,,ENSG00000244094,Small proline rich protein 2F,1,153112114-153113515,Predicted intracellular proteins,Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,9,esophagus: 167.0;ovary: 83.7;tonsil: 63.0,testis: 11.8,Cell line enriched,9.0,K-562: 2.4
41,ADGRF4,"FLJ38076, GPR115, PGR18",ENSG00000153294,Adhesion G protein-coupled receptor F4,6,47685864-47722021,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"HPA007131, HPA007158",Enhanced,,Uncertain,Mitochondria,Pancreatic cancer:5.52e-4 (unfavourable),Mixed,Group enriched,8,esophagus: 12.1;skin: 45.8,tonsil: 3.7,Cell line enhanced,,HaCaT: 11.5;HBEC3-KT: 14.9;hTCEpi: 22.8;U-87 MG: 25.8
42,ALOX12,12S-LOX,ENSG00000108839,"Arachidonate 12-lipoxygenase, 12S type",17,6996065-7010736,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA010691, CAB019287",Approved,,Supported,Nuclear speckles<br>Cytosol,,Mixed,Group enriched,8,esophagus: 50.3;skin: 25.9,gallbladder: 5.0,Group enriched,5.0,A-431: 22.4;HEL: 36.7
43,DEFB4A,"DEFB-2, DEFB102, DEFB2, DEFB4, HBD-2, SAP1",ENSG00000171711,Defensin beta 4A,8,7894629-7896711,"Predicted secreted proteins, Transporters",Evidence at protein level,,,,,,,Group enriched,Group enriched,8,esophagus: 6.0;gallbladder: 10.4;tonsil: 12.3,"cervix, uterine: 1.2",Cell line enhanced,,EFO-21: 2.4
44,DSP,"DPI, DPII, KPPS2, PPKS2",ENSG00000096696,Desmoplakin,6,7541575-7586717,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB037324, HPA045840, HPA054950",Enhanced,,Enhanced,Cell Junctions,"Renal cancer:1.53e-9 (favourable), Urothelial cancer:1.82e-4 (unfavourable)",Tissue enhanced,Group enriched,8,esophagus: 345.7;skin: 1016.4,placenta: 89.1,Cell line enhanced,,BEWO: 263.2;HaCaT: 265.1;hTCEpi: 482.9
45,PAX9,,ENSG00000198807,Paired box 9,14,36657568-36679715,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA038462,Enhanced,,Approved,Nucleoplasm<br>Mitochondria,Cervical cancer:5.38e-4 (favourable),Mixed,Group enriched,8,esophagus: 56.1;parathyroid gland: 102.3;salivary gland: 21.7,tonsil: 7.5,Cell line enhanced,,HDLM-2: 44.7;PC-3: 18.6
46,SFN,YWHAS,ENSG00000175793,Stratifin,1,26863138-26864457,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB006268, HPA011105, CAB040552",Enhanced,,Supported,Cytosol,"Renal cancer:7.45e-6 (unfavourable), Liver cancer:5.68e-5 (unfavourable), Endometrial cancer:1.92e-4 (favourable), Pancreatic cancer:6.01e-4 (unfavourable)",Expressed in all,Group enriched,8,esophagus: 1090.0;skin: 1156.7,tonsil: 132.7,Cell line enhanced,,A-431: 663.2;HaCaT: 1030.0;HBEC3-KT: 1288.5;hTCEpi: 852.9
47,TMEM40,FLJ11036,ENSG00000088726,Transmembrane protein 40,3,12733525-12769457,Predicted membrane proteins,Evidence at protein level,HPA044165,Enhanced,,Approved,Cytosol,,Tissue enhanced,Group enriched,8,esophagus: 88.8;placenta: 23.3;skin: 55.5;tonsil: 23.7,urinary bladder: 6.1,Cell line enhanced,,HBEC3-KT: 182.0;hTCEpi: 40.5;hTERT-HME1: 54.0
48,ALDH3A1,ALDH3,ENSG00000108602,Aldehyde dehydrogenase 3 family member A1,17,19737984-19748943,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB045957, HPA051150, HPA063783",Enhanced,,Enhanced,Vesicles<br>Plasma membrane<br>Cytosol,Head and neck cancer:7.55e-5 (favourable),Mixed,Group enriched,7,esophagus: 406.1;skin: 84.3;stomach: 207.2,tonsil: 31.0,Cell line enriched,21.0,A549: 4306.9
49,ANXA8L1,"ANXA8L2, bA145E20.2, bA301J7.3",ENSG00000264230,Annexin A8-like 1,10,46375627-46537864,Predicted intracellular proteins,Evidence at protein level,"HPA045246, HPA047451",,,Approved,Nucleoplasm,,Mixed,Group enriched,7,esophagus: 199.3;skin: 460.9,urinary bladder: 44.2,Cell line enhanced,,HaCaT: 384.4;HBEC3-KT: 476.5;hTCEpi: 124.5;SiHa: 166.0
50,ARHGAP40,"C20orf95, dJ1100H13.4",ENSG00000124143,Rho GTPase activating protein 40,20,38601934-38651035,Predicted intracellular proteins,Evidence at protein level,"HPA042636, HPA042840",Uncertain,,Supported,Nucleoplasm<br>Plasma membrane<br>Centrosome<br>Cytosol,Renal cancer:2.89e-4 (unfavourable),Mixed,Group enriched,7,breast: 38.1;epididymis: 43.7;esophagus: 12.6;seminal vesicle: 11.3;skin: 53.8,prostate: 4.4,Cell line enhanced,,BEWO: 8.0;HBEC3-KT: 9.7;RPTEC TERT1: 8.8;SK-BR-3: 9.5;T-47d: 14.4
51,BNIPL,"BNIP-S, BNIP-Salpha, BNIP-Sbeta, BNIPl-1, BNIPL-2, PP753",ENSG00000163141,BCL2 interacting protein like,1,151036570-151047600,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA019946,,,Approved,Cytosol,"Thyroid cancer:4.32e-4 (favourable), Endometrial cancer:6.50e-4 (unfavourable)",Mixed,Group enriched,7,esophagus: 88.9;skin: 227.0,breast: 21.6,Cell line enriched,14.0,T-47d: 44.3
52,EPHX3,"ABHD9, FLJ22408",ENSG00000105131,Epoxide hydrolase 3,19,15226919-15233435,Predicted secreted proteins,Evidence at transcript level,HPA012842,Uncertain,,,,Head and neck cancer:2.27e-5 (favourable),Tissue enhanced,Group enriched,7,esophagus: 35.1;skin: 62.8;tonsil: 24.3,parathyroid gland: 5.5,Cell line enhanced,,EFO-21: 2.3;NTERA-2: 2.3;SCLC-21H: 1.2
53,IL36RN,"FIL1, FIL1(DELTA), FIL1D, IL-1F5, IL1F5, IL1HY1, IL1L1, IL1RP3, IL36RA, MGC29840",ENSG00000136695,Interleukin 36 receptor antagonist,2,113058638-113065382,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA034542,Uncertain,,,,,Tissue enriched,Group enriched,7,esophagus: 17.2;skin: 40.7;tonsil: 38.1,placenta: 4.7,Group enriched,18.0,BEWO: 25.1;U-87 MG: 19.4
54,IVL,,ENSG00000163207,Involucrin,1,152908545-152911886,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002243, HPA055211",Enhanced,,Supported,Nuclear bodies<br>Centrosome<br>Cytosol,,Group enriched,Group enriched,7,esophagus: 308.3;skin: 131.2,tonsil: 32.9,Group enriched,24.0,HaCaT: 256.2;RT4: 61.2;SK-BR-3: 64.8
55,KRT15,"CK15, K15, K1CO",ENSG00000171346,Keratin 15,17,41513743-41522529,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA023910, HPA024554",Enhanced,,Supported,Nucleoplasm<br>Intermediate filaments,Breast cancer:4.50e-4 (favourable),Tissue enhanced,Group enriched,7,breast: 321.5;esophagus: 784.4;skin: 1010.3,prostate: 94.7,Group enriched,12.0,HaCaT: 732.6;hTCEpi: 454.1
56,MYH3,"HEMHC, MYHC-EMB, MYHSE1, SMHCE",ENSG00000109063,Myosin heavy chain 3,17,10628526-10657309,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA021808,Enhanced,,,,,Mixed,Group enriched,7,esophagus: 9.7;prostate: 46.3;seminal vesicle: 24.5,"testis,urinary bladder: 4.0",Cell line enriched,30.0,HSkMC: 43.3
57,PPL,,ENSG00000118898,Periplakin,16,4882507-4960741,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA042550, HPA059859",Enhanced,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Ovarian cancer:2.76e-4 (unfavourable),Expressed in all,Group enriched,7,esophagus: 558.8;skin: 149.5,tonsil: 52.0,Cell line enhanced,,HaCaT: 168.9;SiHa: 108.6
58,SERPINB3,"HsT1196, SCC, SCCA1, T4-A",ENSG00000057149,Serpin family B member 3,18,63655197-63661963,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB018772, CAB036006, CAB036007, HPA048341, HPA049988, HPA055992",Enhanced,,Approved,Plasma membrane<br>Cytosol,Pancreatic cancer:3.19e-4 (unfavourable),Tissue enhanced,Group enriched,7,"cervix, uterine: 298.5;esophagus: 848.0",urinary bladder: 87.5,Cell line enhanced,,HaCaT: 5.5;SiHa: 4.1;U-2197: 7.3
59,TGM5,TGX,ENSG00000104055,Transglutaminase 5,15,43232595-43266857,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,,Mixed,Group enriched,7,esophagus: 8.4;skin: 22.3,breast: 2.3,Cell line enriched,8.0,HEL: 16.7
60,TMPRSS11F,FLJ16046,ENSG00000198092,"Transmembrane protease, serine 11F",4,68053198-68129880,"Enzymes, Predicted membrane proteins",Evidence at transcript level,HPA026911,Uncertain,,,,,Group enriched,Group enriched,7,esophagus: 16.7;skin: 11.0;tonsil: 3.7,breast: 1.5,Cell line enhanced,,K-562: 1.4
61,ALDH3B2,ALDH8,ENSG00000132746,Aldehyde dehydrogenase 3 family member B2,11,67662162-67681200,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA045132,Enhanced,,,,,Mixed,Group enriched,6,breast: 89.9;esophagus: 103.4;skin: 122.2,tonsil: 19.0,Cell line enhanced,,MCF7: 49.6;SK-BR-3: 48.3;T-47d: 12.2
62,ANKRD35,FLJ25124,ENSG00000198483,Ankyrin repeat domain 35,1,145866560-145885866,Predicted intracellular proteins,Evidence at protein level,HPA035453,Enhanced,,,,"Cervical cancer:2.90e-4 (favourable), Breast cancer:9.35e-4 (favourable)",Mixed,Group enriched,6,"cervix, uterine: 30.8;esophagus: 16.6;skin: 69.8",tonsil: 6.1,Cell line enhanced,,ASC TERT1: 6.6;THP-1: 4.5;TIME: 6.9;U-87 MG: 8.1;U-937: 5.9
63,ARSF,,ENSG00000062096,Arylsulfatase F,X,3041471-3112726,Predicted membrane proteins,Evidence at protein level,HPA000549,,,Uncertain,Cytosol,,Tissue enhanced,Group enriched,6,adrenal gland: 4.0;cerebral cortex: 2.1;epididymis: 2.0;esophagus: 2.3;kidney: 8.0;skin: 6.7,liver: 0.6,Not detected,,
64,CD1A,CD1,ENSG00000158477,CD1a molecule,1,158254137-158258269,"CD markers, Predicted membrane proteins",Evidence at protein level,"CAB000009, HPA010734",Enhanced,,,,Cervical cancer:6.37e-4 (favourable),Mixed,Group enriched,6,esophagus: 9.5;skin: 27.0,"lymph node,tonsil: 2.9",Cell line enriched,122.0,MOLT-4: 48.8
65,CEACAM6,"CD66c, NCA",ENSG00000086548,Carcinoembryonic antigen related cell adhesion molecule 6,19,41750977-41772208,"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB008370, HPA011041",Enhanced,,,,,Mixed,Group enriched,6,bone marrow: 110.7;colon: 180.6;esophagus: 173.5;gallbladder: 189.0;lung: 405.6;rectum: 233.8,appendix: 37.6,Cell line enriched,9.0,A549: 140.1
66,CLCA4,CaCC2,ENSG00000016602,Chloride channel accessory 4,1,86547078-86580754,Predicted membrane proteins,Evidence at protein level,HPA017045,Uncertain,,,,"Colorectal cancer:7.47e-4 (favourable), Head and neck cancer:8.63e-4 (favourable)",Tissue enhanced,Group enriched,6,colon: 249.5;esophagus: 365.5;rectum: 158.4,urinary bladder: 41.0,Cell line enriched,1215.0,RT4: 342.2
67,ECM1,,ENSG00000143369,Extracellular matrix protein 1,1,150508062-150513789,"Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA027241,Enhanced,,Approved,Nucleoplasm<br>Cytosol,"Renal cancer:1.51e-9 (unfavourable), Urothelial cancer:1.20e-5 (unfavourable), Pancreatic cancer:3.55e-4 (unfavourable)",Expressed in all,Group enriched,6,epididymis: 581.9;esophagus: 989.7,tonsil: 122.7,Cell line enhanced,,ASC TERT1: 277.2;BJ hTERT+: 233.5;fHDF/TERT166: 213.1;hTEC/SVTERT24-B: 192.3
68,ENDOU,"P11, PP11, PRSS26",ENSG00000111405,"Endonuclease, poly(U) specific",12,47709734-47725567,Predicted secreted proteins,Evidence at protein level,"HPA012388, HPA067448",Enhanced,,,,Head and neck cancer:6.29e-4 (favourable),Tissue enhanced,Group enriched,6,esophagus: 70.3;skin: 24.9,tonsil: 7.7,Cell line enhanced,,Daudi: 1.6;SK-BR-3: 3.6
69,GJB5,CX31.1,ENSG00000189280,Gap junction protein beta 5,1,34755047-34758512,"Cancer-related genes, Predicted membrane proteins",Evidence at transcript level,HPA038146,Uncertain,,,,Pancreatic cancer:1.54e-4 (unfavourable),Group enriched,Group enriched,6,esophagus: 56.4;skin: 77.4,tonsil: 11.4,Cell line enhanced,,A-431: 25.3;HaCaT: 80.2;HBEC3-KT: 29.1;hTCEpi: 106.2;RT4: 40.6
70,JUP,"CTNNG, DP3, DPIII, PDGB, PKGB",ENSG00000173801,Junction plakoglobin,17,41754604-41786931,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002139, HPA032047",Supported,,Enhanced,Vesicles<br>Plasma membrane<br>Cell Junctions,Renal cancer:2.06e-10 (favourable),Expressed in all,Group enriched,6,esophagus: 491.8;skin: 785.5,fallopian tube: 113.8,Cell line enhanced,,HaCaT: 960.4;RT4: 536.8
71,KLK8,"HNP, neuropsin, ovasin, PRSS19, TADG14",ENSG00000129455,Kallikrein related peptidase 8,19,50996007-51002711,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB019393, HPA035761",Enhanced,,Approved,Vesicles,"Pancreatic cancer:1.10e-4 (unfavourable), Endometrial cancer:2.31e-4 (unfavourable), Lung cancer:5.72e-4 (unfavourable), Urothelial cancer:6.17e-4 (unfavourable)",Tissue enhanced,Group enriched,6,esophagus: 77.9;fallopian tube: 20.9;skin: 96.8,breast: 11.0,Group enriched,7.0,A-431: 76.9;CAPAN-2: 98.5;HaCaT: 73.3
72,KRT16,NEPPK,ENSG00000186832,Keratin 16,17,41609778-41615899,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB000136, HPA000539",Approved,,Approved,Intermediate filaments,Pancreatic cancer:1.09e-5 (unfavourable),Group enriched,Group enriched,6,esophagus: 477.8;tonsil: 102.4,seminal vesicle: 52.5,Cell line enriched,9.0,hTCEpi: 593.7
73,KRT3,"CK3, K3",ENSG00000186442,Keratin 3,12,52789685-52796117,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,6,esophagus: 1.3;skin: 1.8,tonsil: 0.2,Group enriched,8.0,HaCaT: 8.3;HMC-1: 4.9
74,KRT31,"Ha-1, KRTHA1",ENSG00000094796,Keratin 31,17,41393724-41397592,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA049550, HPA055194",Supported,,,,,Group enriched,Group enriched,6,esophagus: 4.6;skin: 14.4,skeletal muscle: 1.5,Not detected,,
75,LGALS7,"GAL7, LGALS7A, PIG1, TP53I1",ENSG00000205076,Galectin 7,19,38770971-38773492,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001549, CAB032606",Enhanced,,,,,Group enriched,Group enriched,6,breast: 18.1;esophagus: 24.3;skin: 27.7,skeletal muscle: 3.6,Cell line enhanced,,HaCaT: 6.2;SCLC-21H: 1.2
76,LYPD3,C4.4A,ENSG00000124466,LY6/PLAUR domain containing 3,19,43460787-43465660,Predicted membrane proteins,Evidence at protein level,"HPA041529, HPA041797, HPA077859",Enhanced,,Approved,Endoplasmic reticulum<br>Vesicles,Lung cancer:7.86e-5 (unfavourable),Tissue enhanced,Group enriched,6,esophagus: 673.8;skin: 593.4,tonsil: 114.6,Cell line enhanced,,HaCaT: 85.1;MCF7: 84.1;RT4: 83.0;SK-BR-3: 114.6
77,NMU,,ENSG00000109255,Neuromedin U,4,55595229-55636698,Predicted secreted proteins,Evidence at protein level,HPA025926,Uncertain,,,,"Renal cancer:4.07e-10 (unfavourable), Endometrial cancer:2.60e-5 (unfavourable)",Mixed,Group enriched,6,esophagus: 34.9;skin: 45.4,tonsil: 6.8,Cell line enhanced,,HaCaT: 336.7;K-562: 278.2
78,PERP,"dJ496H19.1, KCP1, KRTCAP1, PIGPC1, THW",ENSG00000112378,"PERP, TP53 apoptosis effector",6,138088505-138107511,Predicted membrane proteins,Evidence at protein level,HPA022269,Enhanced,,,,"Pancreatic cancer:1.05e-5 (unfavourable), Lung cancer:3.73e-4 (unfavourable), Breast cancer:5.46e-4 (unfavourable)",Expressed in all,Group enriched,6,esophagus: 571.9;skin: 1235.5,breast: 151.1,Cell line enhanced,,hTCEpi: 661.0
79,PGLYRP4,"PGLYRPIbeta, PGRP-Ibeta, PGRPIB, SBBI67",ENSG00000163218,Peptidoglycan recognition protein 4,1,153330120-153348840,Predicted secreted proteins,Evidence at protein level,CAB025879,,,Approved,Vesicles<br>Plasma membrane,,Group enriched,Group enriched,6,esophagus: 5.8;skin: 18.2,tonsil: 2.1,Cell line enhanced,,HaCaT: 3.4;HDLM-2: 2.4;Karpas-707: 1.4
80,RNF222,,ENSG00000189051,Ring finger protein 222,17,8390704-8397826,Predicted membrane proteins,Evidence at transcript level,HPA048916,Uncertain,,,,,Tissue enhanced,Group enriched,6,esophagus: 9.7;skin: 4.1;tonsil: 2.0,bone marrow: 0.9,Cell line enriched,7.0,SK-BR-3: 5.1
81,S100A9,"60B8AG, CAGB, CFAG, CGLB, LIAG, MAC387, MIF, MRP14, NIF, P14",ENSG00000163220,S100 calcium binding protein A9,1,153357854-153361027,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA004193, CAB009441",Enhanced,,Supported,Nucleoplasm<br>Cell Junctions<br>Cytosol,"Liver cancer:1.13e-6 (unfavourable), Renal cancer:8.10e-4 (unfavourable)",Expressed in all,Group enriched,6,bone marrow: 20959.3;esophagus: 24239.1,tonsil: 3911.6,Cell line enriched,5.0,SK-BR-3: 1782.7
82,SDR16C5,"EPHD-2, RDH-E2, RDHE2",ENSG00000170786,Short chain dehydrogenase/reductase family 16C member 5,8,56300010-56320776,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA025224,Enhanced,,,,Head and neck cancer:7.88e-4 (favourable),Mixed,Group enriched,6,breast: 15.2;esophagus: 36.3;lung: 40.3;skin: 72.9;small intestine: 21.7;stomach: 21.0;tonsil: 25.3,"cervix, uterine: 5.6",Cell line enhanced,,CAPAN-2: 22.6;HaCaT: 11.3;hTCEpi: 15.1;T-47d: 9.2
83,SERPINB2,"HsT1201, PAI2, PLANH2",ENSG00000197632,Serpin family B member 2,18,63871692-63903890,"Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA015480,Supported,,,,Urothelial cancer:1.55e-5 (unfavourable),Tissue enhanced,Group enriched,6,esophagus: 260.7;placenta: 70.3;skin: 105.8;tonsil: 72.9,bone marrow: 22.2,Group enriched,6.0,HaCaT: 611.4;U-138 MG: 792.9;U-2197: 1151.1
84,SOX21,SOX25,ENSG00000125285,SRY-box 21,13,94709622-94712399,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,"HPA048337, HPA064084",Approved,,Approved,Nucleus,"Glioma:1.34e-4 (favourable), Cervical cancer:7.60e-4 (favourable)",Tissue enhanced,Group enriched,6,cerebral cortex: 17.9;esophagus: 6.9;skin: 19.4;stomach: 33.4,tonsil: 3.1,Cell line enhanced,,AF22: 80.6;HAP1: 12.8;NTERA-2: 22.0;PC-3: 11.6
85,TMEM79,"FLJ16057, FLJ32254, MATT, MGC13102",ENSG00000163472,Transmembrane protein 79,1,156282935-156293185,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA055214,Enhanced,,Approved,Nucleoli fibrillar center,"Renal cancer:4.31e-7 (unfavourable), Liver cancer:2.61e-5 (unfavourable)",Expressed in all,Group enriched,6,esophagus: 61.6;prostate: 45.5;skin: 66.8,tonsil: 10.3,Mixed,,
86,TRIM29,"ATDC, FLJ36085",ENSG00000137699,Tripartite motif containing 29,11,120111275-120185529,Predicted intracellular proteins,Evidence at protein level,HPA020053,Enhanced,,Supported,Nucleoplasm<br>Intermediate filaments,"Endometrial cancer:2.88e-4 (unfavourable), Pancreatic cancer:4.46e-4 (unfavourable), Stomach cancer:4.93e-4 (favourable)",Tissue enhanced,Group enriched,6,esophagus: 400.3;skin: 455.7,tonsil: 68.3,Cell line enhanced,,HaCaT: 211.2;hTCEpi: 225.5;RT4: 101.2;SiHa: 190.1
87,AKR1C2,"BABP, DD, DD2, DDH2, HAKRD, MCDR2, TDD",ENSG00000151632,Aldo-keto reductase family 1 member C2,10,4987400-5018031,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB047304, HPA068265",Enhanced,,Approved,Nucleus<br>Nucleoli fibrillar center<br>Endoplasmic reticulum<br>Cytosol,,Group enriched,Group enriched,5,adipose tissue: 330.4;breast: 105.2;esophagus: 94.9;gallbladder: 151.9;liver: 161.4;stomach: 126.5;urinary bladder: 143.0,duodenum: 29.8,Cell line enhanced,,A549: 1864.0;ASC diff: 1674.9;Hep G2: 2661.0;RT4: 940.6
88,CLCA2,CLCRG2,ENSG00000137975,Chloride channel accessory 2,1,86424086-86456558,Predicted membrane proteins,Evidence at protein level,HPA047192,Enhanced,,Supported,Nucleus<br>Plasma membrane<br>Cell Junctions,,Group enriched,Group enriched,5,esophagus: 126.4;skin: 102.7,tonsil: 22.5,Cell line enhanced,,BEWO: 36.7;HBEC3-KT: 23.7;hTCEpi: 148.8
89,CSTA,"STF1, STFA",ENSG00000121552,Cystatin A,3,122325244-122341972,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB000469, HPA001031, CAB047315",Enhanced,,Approved,Nucleus<br>Cytosol,"Renal cancer:2.60e-6 (unfavourable), Head and neck cancer:5.86e-4 (favourable)",Expressed in all,Group enriched,5,esophagus: 3876.3;tonsil: 833.8,skin: 429.8,Cell line enhanced,,hTCEpi: 870.0;THP-1: 525.5;U-698: 341.3
90,GJB6,"CX30, DFNA3, ED2, EDH, HED",ENSG00000121742,Gap junction protein beta 6,13,20221971-20232395,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA014846,,,Supported,Cell Junctions,,Tissue enhanced,Group enriched,5,bone marrow: 48.1;cerebral cortex: 39.4;esophagus: 150.1;skin: 32.1,tonsil: 12.2,Cell line enriched,9.0,RT4: 133.4
91,IL22RA1,"CRF2-9, IL22R",ENSG00000142677,Interleukin 22 receptor subunit alpha 1,1,24119771-24143121,Predicted membrane proteins,Evidence at protein level,,,,,,,Mixed,Group enriched,5,colon: 11.3;duodenum: 20.2;esophagus: 10.1;pancreas: 26.1;rectum: 10.9;skin: 38.7;small intestine: 31.3,gallbladder: 4.0,Cell line enhanced,,CACO-2: 9.3;HaCaT: 4.5;Hep G2: 5.5
92,KLK6,"Bssp, Klk7, neurosin, PRSS18, PRSS9",ENSG00000167755,Kallikrein related peptidase 6,19,50958631-50969673,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA051837,,,Supported,Nucleoplasm<br>Nuclear membrane<br>Cytokinetic bridge,"Endometrial cancer:1.38e-5 (unfavourable), Urothelial cancer:1.27e-4 (unfavourable), Pancreatic cancer:7.82e-4 (unfavourable), Lung cancer:8.85e-4 (unfavourable)",Tissue enhanced,Group enriched,5,cerebral cortex: 78.6;esophagus: 63.0;fallopian tube: 44.9;tonsil: 31.3,kidney: 10.2,Group enriched,15.0,A-431: 496.5;CAPAN-2: 1158.9
93,KLK7,"PRSS6, SCCE",ENSG00000169035,Kallikrein related peptidase 7,19,50976482-50984099,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA018994, CAB026342, HPA062126",Enhanced,,Supported,Nuclear membrane<br>Plasma membrane,"Endometrial cancer:8.06e-5 (unfavourable), Pancreatic cancer:1.16e-4 (unfavourable)",Tissue enhanced,Group enriched,5,esophagus: 68.7;skin: 219.6,fallopian tube: 27.9,Group enriched,6.0,CAPAN-2: 7.1;HaCaT: 28.1
94,LEXM,"C1orf177, FLJ40201, LEM",ENSG00000162398,Lymphocyte expansion molecule,1,54806063-54842252,Predicted intracellular proteins,Evidence at protein level,"HPA035889, HPA035890",Uncertain,,,,,Mixed,Group enriched,5,esophagus: 10.5;testis: 7.0,duodenum: 1.6,Not detected,,
95,MAB21L3,"C1orf161, FLJ38716",ENSG00000173212,Mab-21 like 3,1,116111755-116135240,Predicted intracellular proteins,Evidence at protein level,"HPA039551, HPA046187",Uncertain,,Approved,Nucleoplasm,,Mixed,Group enriched,5,esophagus: 7.5;skin: 7.2,"colon,kidney,rectum: 1.3",Cell line enhanced,,BEWO: 3.7;EFO-21: 8.0;RT4: 10.4
96,MYEOV,OCIM,ENSG00000172927,Myeloma overexpressed,11,69294138-69367726,Predicted membrane proteins,Evidence at transcript level,HPA012949,Uncertain,,Approved,Nucleus<br>Vesicles,"Pancreatic cancer:1.54e-7 (unfavourable), Renal cancer:1.48e-5 (unfavourable), Lung cancer:2.00e-4 (unfavourable)",Mixed,Group enriched,5,adipose tissue: 4.0;breast: 5.8;esophagus: 9.2;skin: 1.8;stomach: 6.8,appendix: 1.0,Cell line enhanced,,A-431: 154.1;A549: 74.9;U-2 OS: 38.7
97,MYH8,"MyHC-peri, MyHC-pn",ENSG00000133020,Myosin heavy chain 8,17,10390322-10421950,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001349, CAB016527",Enhanced,,,,,Tissue enhanced,Group enriched,5,esophagus: 16.9;skeletal muscle: 5.5,prostate: 2.2,Cell line enriched,10.0,HSkMC: 5.2
98,SERPINB11,EPIPIN,ENSG00000206072,Serpin family B member 11 (gene/pseudogene),18,63647579-63726432,"Plasma proteins, Predicted intracellular proteins",Evidence at transcript level,,,,,,,Tissue enhanced,Group enriched,5,esophagus: 28.7;prostate: 49.9,tonsil: 7.2,Not detected,,
99,SERPINB5,"maspin, PI5",ENSG00000206075,Serpin family B member 5,18,63476761-63505085,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB009570, HPA019025, HPA019132, HPA020136",Enhanced,,Supported,Vesicles,"Pancreatic cancer:5.71e-6 (unfavourable), Lung cancer:1.54e-4 (unfavourable)",Tissue enhanced,Group enriched,5,esophagus: 220.2;skin: 261.8,breast: 44.2,Cell line enhanced,,HaCaT: 1048.4;HBEC3-KT: 281.3;hTCEpi: 583.7
